Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes    » A1c    » Adolescents    » Awareness    » Cause    » Children    » Complications    » Control    » Costs    » Cure    » Diagnosis    » Drugs    » Elderly    » Gestational    » Hypoglycemia    » Impaired Fasting Glucose    » Impaired Glucose Tolerance    » Inflammation    » Insulin Resistance    » Insulin Sensitivity    » Men    » Metabolic Syndrome    » Minorities    » Obesity    » Organs    » Other Diseases    » Pancreas    » Pre-Diabetes    » Prevention    » Research    » Risk Factors    » Screening    » Statistics    » Stress    » Syndrome X    » Testing    » Treatments    » Type 1    » Type 2    » Warning Signs    » Women Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

About Diabetes » Testing

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Januvia™ Works For for First and Second-Line Management of Type 2 Diabetes Posted: Thursday, November 16, 2006

The FDA has approved sitagliptin for use with diet and exercise or in combination with metformin or the TZDs to improve glycemic control in adult patients with type 2 diabetes.

Three Years Later, Participants in the Diabetes Prevention Study Still Benefiting Posted: Thursday, November 16, 2006

The effects of lifestyle intervention on diabetes risk do not disappear after active counseling has stopped, a new follow-up of the Finnish Diabetes Prevention Study shows.

Acomplia ™(Rimonabant) Receives 1st Marketing Authorization in North America Posted: Thursday, November 16, 2006

Acomplia™ (rimonabant) approved in Mexico to treat obese/overweight patients with associated type 2 diabetes or dyslipidemia or to help them improve glycemic control on background of conventional antidiabetic treatment.

Born in the USA, One in Three Will Develop Diabetes Posted: Thursday, November 09, 2006

Fifty-four million Americans - that’s one in six of us -- have pre-diabetes and most don’t even realize it.

RESULTS IN! The Most Effective and Safe Method for Diabetes Prevention IS……. Posted: Thursday, November 09, 2006

Lifestyle Intervention Remains the Most Effective and Safe Method for Diabetes Prevention.

Importance of Fasting Hyperglycemia Dependent on HbA1c Posted: Thursday, November 09, 2006

Study concluded that the contribution of fasting hyperglycemia was greater in patients with increased HbA1c.

Test Predicts Risk for High and Low Blood Sugar Levels Posted: Thursday, November 09, 2006

The average daily risk range, a measure computed from an individual's blood sugar readings, is useful in predicting both low and high blood sugar levels.

Increasing A1c Levels Predicts Progession to Type 1 Diabetes Posted: Thursday, November 02, 2006

Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

Switch To Insulin Pen Improves Clinical Outcomes And Reduces Medical Costs Posted: Thursday, November 02, 2006

Total all-cause annual treatment costs reduced by $1590 per patient.

Can Providing Free Strips to Self-Monitor Type 2 Diabetes Improve Control? Posted: Thursday, November 02, 2006

According to one study it does not. But the study was flawed in that they did not educate the patient as what to do with the information.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.